Formulation, characterization and optimization of Hepatitis B surface antigen (HBsAg)-loaded chitosan microspheres for oral delivery

Pharmaceutical Development and Technology

Volumn 17, Issue 2, 2012, Pages 251-258

  Premaletha, K ^a   Licy, C D ^b   Jose, Sajan ^c   Saraladevi, A ^d   Shirwaikar, Annie ^b   Shirwaikar, Arun ^e  

^a Academy of Pharmaceutical Sciences   (India)

^b MANIPAL UNIVERSITY   (India)

^c MAHATMA GANDHI UNIVERSITY   (India)

^d Academy of Medical Sciences   (India)

^e GULF MEDICAL UNIVERSITY   (United Arab Emirates)

Author keywords

Chitosan microspheres; Emulsion solvent evaporation; HBsAg; Oral vaccine

Indexed keywords

APROTININ; BACITRACIN; CHITOSAN; CHITOSAN MICROSPHERE; HEPATITIS B SURFACE ANTIGEN; MICROSPHERE; PENETRATION ENHANCING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; EMULSION; EVAPORATION; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; PARTICLE SIZE; PRIORITY JOURNAL; ROOM TEMPERATURE;

ADMINISTRATION, ORAL; ANIMALS; CHITOSAN; DRUG CARRIERS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; MICROSPHERES; RABBITS;

EID: 84857387445     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2010.535824     Document Type: Article

References (27)

1. UNICEF press release: Low investment in immunization and vaccines threatens global health. 20 Nov 2002. Accessed 12 January 2010 from the website: http://www.unicef.org/ newsline/02pr61sowv.htm.
2. Nelson CM, Wibisono H, Purwanto I, Mansyur V, Moniaga A, Widjaya. Hepatitis B vaccine freezing in the Indonesian cold chain: Evidence and solutions. Bull WHO 2004;82:99-105.
3. Borges O, Cordeiro-da-Silva A, Tavarus J, Santarem N, Borchard G, Junginger HE, de Sousa A. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm 2008;69:405-416.
4. Simani OE, Leroux-Roels G, Francois G, Burnett RJ, Meheus A, Mphahlele MJ. Reduced detection and levels of protectiveantibodies to hepatitis B vaccine in under 2-year-old HIV positive South African children at a paediatric outpatient clinic. Vaccine 2009;27:146-151.
5. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089-2094.
6. Kew MC. Epidemiology of hepatocellular carcinoma. Toxicology 2002;181-182:35-38.
7. Kane MA. Global programme for control of hepatitis infection. Vaccine 1995;13:(Suppl. 1):S47-49.
8. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of blood borne pathogens: A review. Bull WHO 1999;77:789-800.
9. Jodar L, Duclos P, Milstien JB, Griffiths E, Aguado MT, Clements CJ. Ensuring vaccine safety in immunization programmes - a WHO perspective. Vaccine 2001;19:1594-1605.
10. Clements CJ, Larsen G, Jodar L. Technologies that make administration of vaccines safer. Vaccine 2004;22:2054-2058.
11. Partidos CD, Beignon AS, Brown F, Kramer E, Briand JP, Muller S. Applying peptide antigens onto bare skin: Induction of humoral and cellular immune responses and potential for vaccination. J Control Release 2002;85:27-34.
12. Thanavala Y, Mahoney M, Pal S, Scott A, Richter L, Natarajan N, Goodwin P, Arntzen CJ, Mason HS. Immunogenicity in humans of an edible vaccine for hepatitis B. Proc Natl Acad Sci USA 2005;102:3378-3382.
13. Cole ET, Cade D, Benameur H. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration. Adv Drug Deliv Rev 2008;60:747-756.
14. Sreenivas P, Erdal C, Mohammed GZ, Satyanarayana S, Alpar HO. Enhancement of immune response of HBsAg loaded poly (L-lactic acid) microspheres against Hepatitis B through incorporation of alum and chitosan. J Microencapsul 2007;24(6):539-552.
15. Jaganathan KS, Vyas SP. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant Hepatitis B antigen administered intranasally. Vaccine 2006;24(19):4201-4211.
16. Gasco MR. Lipid nanoparticles: Perspectives and challenges. Adv Drug Deliv Rev 2007;59:377-378.
17. Joshi MD, Muller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009;71:161-172.
18. Tarrago-Trani MT, Storrie B. Alternate routes for drug delivery to the cell interior: Pathways to the Golgi apparatus and endoplasmic reticulum. Adv Drug Deliv Rev 2007;59:782-797.
19. Frenkel V. Ultrasound mediated delivery of drugs and genes to solid tumors. Adv Drug Deliv Rev 2008;60:1193-1208.
20. Hassett DE, Zhang J, Whitton JL. Plasmid DNA vaccines are effective in the absence of IFN?. Virology 1999;263:175-183.
21. Bernkop-Schnurch A. Thiomers: A new generation of mucoadhesive polymers. Adv Drug Deliv Rev 2005;57:1569-1582.
22. Baldwin SL, Bertholet S, Kahn M, Zharkikh I, Ireton GC, Vedvick TS, Reed SG, Coler RN. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 2009;27:3063-3071.
23. Howard JA. Commercialization of plant-based vaccines from research and development to manufacturing. Anim Health Res Rev 2004;5:243-245.
24. Pierige F, Serafini S, Rossi L, Magnani M. Cell-based drug delivery. Adv Drug Deliv Rev 2008;60:286-295.
25. Bies C, Lehr CM, Woodley JF. Lectin mediated drug targeting: History and applications. Adv Drug Deliv Rev 2004;56:425-435.
26. Huang L. Liposomes in ultrasonic drug and gene delivery. Adv Drug Deliv Rev 2008;60:1167-1176.
27. Thanoo BC, Sunny MC, Jayakrishnan A. Cross-linked chitosan microspheres: Preparation and evaluation as a matrix for the controlled release of pharmaceuticals. J Pharm Pharmacol 1992;44:283-286.